Sorachai NitayaphanPunnee PitisuttithumChitraporn KarnasutaChirapa EamsilaMark De SouzaPatricia MorganVictoria PolonisMichael BenensonTom VanCottSilvia Ratto-KimJerome KimDarawan ThapintaRobin GarnerValai BussaratidPricha SingharajRaphaelle El HabibSanjay GurunathanWilliam HeywardDeborah BirxJohn McNeilArthur E. BrownMahidol UniversityChiang Mai UniversityWalter Reed Army Institute of ResearchSanofi Pasteur SAVaxGen, Inc.Armed Forces Research Institute of Medical Sciences, ThailandLeahi HospitalTripler Regional Med CenterNational Institute of Allergy and Infectious Diseases2018-07-242018-07-242004-08-15Journal of Infectious Diseases. Vol.190, No.4 (2004), 702-706002218992-s2.0-20244383550https://repository.li.mahidol.ac.th/handle/20.500.14594/21582ALVAC-HIV (vCP1521) and AIDSVAX B/E were evaluated in a phase 1/2 trial of human immunodeficiency virus (HIV)-negative Thai adults. Of 133 volunteers enrolled, 122 completed the trial. There were no serious vaccine-related adverse events, nor were there intercurrent HIV infections. Lymphoproliferative responses to glycoprotein 120 E were induced in 63% of the volunteers, and HIV-specific CD8 cytotoxic T lymphocyte responses were induced in 24%. Antibody responses increased in frequency and magnitude in association with the dose level of AIDSVAX B/E. Binding and neutralizing antibodies to the MN strain were induced in 100% and 98%, respectively, of the volunteers receiving 600 μg of AIDSVAX B/E, and such antibodies to E strains were induced in 96% and 71%, respectively, of these volunteers. This vaccine combination was well tolerated and was immunogenic, meeting milestones for advancement to phase 3 evaluation.Mahidol UniversityMedicineArticleSCOPUS10.1086/422258